請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44802
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 高嘉宏 | |
dc.contributor.author | Ping-Yeh Wu | en |
dc.contributor.author | 吳炳燁 | zh_TW |
dc.date.accessioned | 2021-06-15T03:55:16Z | - |
dc.date.available | 2010-09-09 | |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-06-25 | |
dc.identifier.citation | 1. Akuta N, Suzuki F, Hirakawa M, et al : Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009 81:1032-9.
2. Akuta N, Suzuki F, Kawamura Y, et al : Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007 46:403-10. 3. Akuta N , Suzuki F, Kawamura Y, et al : Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007 46:1357-64. 4. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135–9. 5. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepaitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. 6. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059–63. 7. Chen DS, Kuo GC, Sung JL, et al : Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990 162:817-22. 8. Chen CL, Yang HI, Yang WS, et al : Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008 135: 111-21. 9. Chu CJ, Lee SD, Hung TH, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2008;29:46-54 10. Conte D, Fraquella M, Pratu D, et al. Prevalance and clinical course of chronic hepatitis C virus infection and rate of HCV vertical transmission in a cohort of 15,250 prenant women. Hepatology 2000; 31(3):751-5 11. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon induced antiviral genes. J Infect Dis. 2005; 191(1):93-9 12. Dore GJ, Law M, MacDonald M, et al. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171-84. 13. Gale M, Foy EM: Evasion of intracellular host defense by hepatitis C virus. Nature 2005 436: 939-45. 14. Georgescu EF, Lonescu R, Florescu G, et al. Steatosis, insulin resistance, iron overload, fibrosis and viral load as negative factors affecting early (EVR) and sustained (SVR) virological response in patients with chronic hepatitis C treated with peginterferon and ribavirin. Hepatology 2008 48:A869. 15. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. : Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49: 1335-74. 16. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009 51(6):984-90. 17. Grimbert S, Valensi P, Levy-Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case–control study. Gastroenterol Clin Biol 1996; 20: 544–8. 18. Hernandez ME, Bruguera M, Puyuelo T, et al. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. J Hepatol 16: 56-8, 1992. 19. Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH & Chen DS. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007; 50:310-5 20. Hui JM, Sud A, Farrell GC, et al : Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125:1695-1704. 21. Kao JH, Chen DS : Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver International 2005 25:696-703. 22. Kao JH, Chen PJ, Lai MY, et al : Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995 21:233-7. 23. Kao JH, Lin HH, Chen PJ, Lai MY, Wang TH, Mizokami M & Chen DS. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996; 31:224-7. 24. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome frm Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87:9524-8. 25. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499–508. 26. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570–6. 27. Ko YC, Ho MS, Chiang TA, et al. Tattooing as a risk of hepatitis C virus infection. J Med Virol 1992; 38: 288-91. 28. Kobayashi M, Akuta N, Suzuki F, et al. Influence of amino acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010; 82: 41-8. 29. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009 44:S82-8. 30. Kwok S, Higuichi R: Avoiding false positives with PCR. Nature 1989; 229: 237-8. 31. Lai MS, Hsieh MS, Chiu YH, et al : Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006 43(6):1295-1302. 32. Lai MY, Kao JH, Yang PM, et al : Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996 111(5): 1307-12. 33. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001 345(1):41-52. 34. Lindenbach BD, Rice CM : Unraveling hepatitis C virus replication from genome to function. Nature 2005 436(7053): 933-8. 35. Liu CH, Liu CJ, Lin CL, et al : Pegylated Interferon-α-2a plus ribavirin for treatment-naive asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomised controlled trial. Clin Infect Disease 2008 47(10):1260-9. 36. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328–33. 37. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology. 2000;31(3):756-62. 38. Neuman MG, Benhamou JP, Martinot M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepa- titis C. Clin Biochem 1999; 32: 537–45 39. Petta S, Camma C, Marco VD, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterology 2008 103:1136-1144. 40. Seeff LB : Natural history of chronic hepatitis C. Hepatology 2002 36(5, Supp 1):S35-46. 41. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009 Suppl 2:13-25. 42. Shintani Y, Fujie H, Miyoshi H, et al : Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126(3):840-8. 43. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol. 1999 ;59(3):290-6 44. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(suppl 1):S99-105. 45. Thomas DL Growing Importance of liver disease in HIV-infected persons. Hepatology 2006, 43(2), Suppl S221-229 46. Vlotides G, Sorensen AS, Kapp F, et al. SOCS-1 and SOCS-3 inhibit IFN-alpha- induced expression of the antiviral pro- tein 2,5-OAS and MxA. Biochem Biophys Res Commun 2004; 320: 1007–14 47. Yu ML, Dai CY, Huang JF et al : A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56(4): 553-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44802 | - |
dc.description.abstract | 研究背景 慢性C型是引發肝硬化、肝癌的重要原因。C肝病毒基因轉譯出結構蛋白與非結構蛋白,其中結構蛋白分為核心蛋白及外套膜蛋白,核心蛋白已知會與許多人體細胞蛋白交互作用。進而影響細胞發炎反應、甚至致癌。此外,核心蛋白可以增加轉殖鼠之胰島素抗性,進而引發糖尿病。由於C肝病毒複製缺乏校正功能,基因容易產生變異。之前的研究顯示,若是C肝病毒核心蛋白胺基酸第70處由Glutamine取代Arginine(R70Q)及第91 處由Methionine取代Leucine(L91M),可能會使得患者接受干擾素合併雷巴威林治療之療效降低,較不易達到快速病毒學反應(RVR)及持續性病毒學反應(SVR)。而日本學者研究也發現C肝病毒核心蛋白胺基酸變異與胰島素抗性有關。針對核心蛋白變異進行研究,可更加了解C肝病毒干擾素抗藥性機轉及與胰島素抗性之相關性。
研究假說 本研究假設感染C型肝炎1b基因型病毒之核心蛋白胺基酸序列變異如R70Q及L91M之患者,於接受干擾素合併雷巴威林治療達到持續性病毒性反應(SVR)比例較低,且合併有較高的胰島素抗性。 研究方法 收集慢性C型肝炎基因型1b患者42 位,接受長效型干擾素合併雷巴威林治療24週,於治療前、第四週及治療完成後六個月檢測血清病毒量,紀錄是否達到RVR及SVR。治療前收集病患基本資料如年齡、性別、BMI,並抽血檢驗血球計數、空腹血糖、胰島素濃度等生化檢驗。病患簽署同意書後,進行肝臟穿刺取得肝組織,由病理學家針對肝纖維化及肝細胞脂肪堆積給予評分。利用PCR方式,將C肝病毒核心蛋白基因放大,取得DNA序列後進行比對,以檢測C肝病毒核心蛋白是否發生R70Q及L91M變異。利用統計分析軟體進行資料分析。 結果 C肝病毒核心蛋白胺基酸70若發生R70Q/H變異,與達到RVR及SVR的比例似乎無關,但R70Q/H變異的患者合併並嚴重胰島素抗性(HOMA-IR≧3.5)比例明顯較未變異組高(60% vs. 26%,P=0.047)。若C肝病毒核心蛋白胺基酸91處發生L91M變異,合併嚴重胰島素抗性比例也較高(56% vs. 25%,P=0.059)。若將R70Q/H與L91M變異與否做比較,雙重野生組達到RVR(72% vs. 42%,P=0.517)及SVR(77.8% vs. 62.5%,P=0.333)似乎較高,而變異組之胰島素抗性明顯高於雙重野生組(7.02±.43 vs. 2.19±1.26,P=0.01)。另多變項分析可知低病毒量者達到SVR機會為高病毒量者的8.7倍(95%CI 1.854-47.540,P=0.013),核心蛋白胺基酸70及91處發生變異亦為合併嚴重胰島素抗性的危險因子。 結論 C型肝炎病毒核心蛋白胺基酸序列第70個胺基酸若是發生R70Q/H變異,及合併第91個胺基酸發生L91M變異較野生型病毒之胰島素抗性(HOMA-IR)有明顯上升,但與血清病毒量、肝臟纖維化程度無關。起始血清病毒量較低、肝臟纖維化程度較輕、年齡≦50歲的病患,接受干擾素合併治療達到SVR機會較高。 | zh_TW |
dc.description.abstract | Background Hepatitis C virus (HCV) infection is an important cause of liver cirrhosis and hepatocellular carcinoma(HCC)worldwide. HCV belongs to the Hepacivirus genus of the Flaviviridae family. It is a spherical particle, 55 to 65 nm in diameter, with an envelope, and consists of the genome of a 9.6-kb plus strand RNA. It has short untranslated regions at both the 5’- and 3’- termini, and the middle region, which accounts for about 95% of the whole genome, encodes a precursor protein consisting of ~3,010 amino acid residues. The coding regions of viral structural proteins such as core as well as E1 and E2 are located at the N-terminus, while the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B are situated at the middle region near the C-terminus. Among these viral proteins, core protein reacts with human proteins and bears multiple regulatory functions including the influence on inflammation and induction of HCC. Besides, it can induce insulin resistance in transgenic mice studies. Previous clinical studies from Japan suggested that patient with amino acid substitutions in HCV core region 70 of Glutamine for Arginine(R70Q)and 91 of Methionine for Leucine(L91M)have lower rates of rapid virologic response (RVR) and sustained virologic response (SVR), and HCV core gene polymorphisms are related to the development of insulin resistance in patients with chronic HCV infection.
Materials and Methods We collected 42 Taiwanese chronic hepatitis C patients with genotype 1b infection. All of them received combination therapy of pegylated interferon alfa-2a plus ribavirin for 24 weeks. Blood samples were collected for complete blood count, fasting glucose, fasting insulin and liver enzymes, pre-treatment HCV RNA. Liver biopsy was also performed to determine the stage of hepatic fibrosis and steatosis. Serum HCV RNA level was assayed at week 4 and 24 of therapy to identify RVR and SVR. HCV core gene polymorphisms of amino acid 70 and 91 were analysed by direct sequencing after PCR amplification. Statistical analysis on the relationship among virologic response to antiviral therapy, insulin resistance and HCV core gene polymorphisms were done. Results Patients with HCV core gene R70Q/H substitution had a higher frequency of more severe insulin resistance(HOMA-IR≧3.5)than those without(60% vs. 26%,P=0.047). Patients with L91M substitution also had similar results(56% vs. 25%,P=0.059). Patients with double wild-type sequences had a higher SVR rate(77.8% vs. 62.5%,P=0.333) and lower insulin resistance(HOMA-IR 2.19±1.26 vs. 7.02±7.43)than those with non-double wild-type sequences. Multivariate analysis suggested that patients with lower viral load tended to achieve a higher SVR rate. In addition, HCV core gene L91M and/or R70Q/H substitution tended to have more severe insulin resistance(Odds ratio 15.598, 95%CI 2.202-110.480, P=0.006.) Conclusions HCV core gene R70Q and /or L91M substitutions are associated with more severe insulin resistance. HCV genotype 1b patients with lower viral load, younger age and lower fibrosis score have a higher likelihood to achieve SVR to combination therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T03:55:16Z (GMT). No. of bitstreams: 1 ntu-99-P95421006-1.pdf: 388924 bytes, checksum: c7cbc94f7bf5154f36ba956947053f22 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 目 錄
口試委員會審定書……………………………………………………Ⅰ 誌謝 ………………………………………………………………… Ⅱ 中文摘要…………………………………………………………… Ⅲ 英文摘要…………………………………………………………… IV 目錄………………………………………………………………… V 圖目錄………………………………………………………………VI 表目錄………………………………………………………………VII 正文…………………………………………………………………VIII 第一章 緒論 第一節 研究背景及文獻回顧……………………………………1 第二節 研究主題及重要性……………………………………..10 第三節 研究假說………………………………………………..11 第四節 研究目的………………………………………………..11 第二章 研究方法與材料…………………………………………….12 第三章 研究結果…………………………………………………….15 第四章 討論………………………………………………………….19 第五章 展望………………………………………………………….22 第六章 英文簡述…………………………………………………… 24 第七章 參考文獻…………………………………………………… 32 第八章 附錄………………………………………………………….36 | |
dc.language.iso | zh-TW | |
dc.title | C型肝炎病毒核心蛋白基因多形性之臨床病理研究 | zh_TW |
dc.title | The Clinicopathologic Study of Core Gene Polymorphisms of Hepatitis C Virus | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 劉俊人,王永衛 | |
dc.subject.keyword | C肝病毒,核心蛋白,基因多形性,胰島素抗性,干擾素, | zh_TW |
dc.subject.keyword | HCV,genotype,core protein,gene polymorphism,insulin resistance,pegylated interferon,ribavirin, | en |
dc.relation.page | 46 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-06-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 379.81 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。